Mark Haden
Corporate Officer/Principal en CLEARMIND MEDICINE INC. .
Fortuna: 160 $ al 30/04/2024
Perfil
Mark Haden is currently the Vice President of Business Development at Clearmind Medicine, Inc. He previously worked as the Director of Clinical Trials at Psygen Labs, Inc. from 2021 to 2022 and as the Executive Director at Multidisciplinary Association for Psychedelic Studies Canada from 2017 to 2021.
Haden received his undergraduate and graduate degrees from the University of British Columbia.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
CLEARMIND MEDICINE INC.
0.00% | 31/10/2023 | 133 ( 0.00% ) | 160 $ | 30/04/2024 |
Cargos activos de Mark Haden
| Empresas | Cargo | Inicio |
|---|---|---|
| CLEARMIND MEDICINE INC. | Corporate Officer/Principal | 01/07/2021 |
Antiguos cargos conocidos de Mark Haden.
| Empresas | Cargo | Fin |
|---|---|---|
Psygen Labs, Inc.
 Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Corporate Officer/Principal | 01/03/2022 |
Formación de Mark Haden.
| University of British Columbia | Graduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| CLEARMIND MEDICINE INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Psygen Labs, Inc.
Psygen Labs, Inc. Pharmaceuticals: GenericHealth Technology Psygen Labs, Inc. is a psychedelics manufacturer that provides non-exclusive access to psychedelic drug products for clinical research and therapeutic applications. The company is based in Calgary, Canada. With over 50 years of combined experience synthesizing psychedelics, the Canadian company is well positioned to be a lead supplier for the emerging commercial market. The CEO of the company is Danny Motyka. | Health Technology |
- Bolsa de valores
- Insiders
- Mark Haden